Immunoadjuvanticity of Novel CpG ODN (Oligodeoxynucleotide) |
Park, Su-Jung
(Department of Microbiology, Yonsei University Wonju College of Medicine)
Cho, Hyeon-Cheol (Department of Microbiology, Yonsei University Wonju College of Medicine) Bae, Keum-Seok (Department of General Surgery, Yonsei University Wonju College of Medicine) Kim, Soo-Ki (Department of Microbiology, Yonsei University Wonju College of Medicine) |
1 | Cooper, C. L. et al. Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine 22:3136-3143 (2004) DOI ScienceOn |
2 | Roberts, T. L., Sweet, M. J., Hume, D. A. & Stacey, K. J. Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioatemodified oligonucleotides. J. Immunol. 174:605-608 (2005) DOI |
3 | Bhattacharjee, R. N. & Akira, S. Modifying toll-like receptor 9 signaling for therapeutic use. Mini Reviews in Medicinal Chemistry 6:287-291 (2006) DOI ScienceOn |
4 | Link, B. K. et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J. Immunother. 29: 558-568 (2006) DOI |
5 | Krieg, A. M. Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochimica et Biophysica Acta 1489:107-116 (1999) DOI ScienceOn |
6 | Chuang, T. H. et al. Toll-like receptor 9 mediates CpG-DNA signaling. Journal of Leukocyte Biology 71:538-544 (2002) |
7 | Carpentier, A. et al. Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma. Neuro-oncology 8:60-66 (2006) DOI ScienceOn |
8 | Becker, Y. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications. Anticancer research 26:1113-1134 (2006) |
9 | Verthelyi, D. & Klinman, D. M. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates. Clinical Immunology Orlando, Fla 109:64-71 (2003) DOI ScienceOn |
10 | Mutwiri, G. K., Nichani, A. K., Babiuk, S. & Babiuk, L. A. Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides. J. Control Release 97:1-17 (2004) DOI ScienceOn |
11 | Dittmer, U. & Olbrich, A. R. Treatment of infectious diseases with immunostimulatory oligodeoxynucleotides containing CpG motifs. Current Opinion in Microbiology 6:472-477 (2003) DOI ScienceOn |
12 | Carpentier, A. F., Auf, G. & Delattre, J. Y. CpG-oligonucleotides for cancer immunotherapy : review of the literature and potential applications in malignant glioma. Front Biosci. 8:e115-127 (2003) DOI |